Researchers have found that melanoma patients may benefit from a holiday from MAPK inhibitors while alternative therapies stave off emergence of resistant melanoma clones.
Skin Cancer / Melanoma Targets
A new triple therapy approach using a checkpoint inhibitor and T-cell therapy is showing considerable promise in the treatment of Merkel cell carcinoma.
Researchers in Seattle are now reporting success with a biopolymer synthetic scaffold loaded with cancer-fighting T cells and a mix of nutrients to potentially combat solid tumors.
The FDA on March 23, 2017, granted accelerated approval to avelumab (Bavencio) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.
Penn State College of Medicine researchers have discovered a new class of drugs that may keep a deadly form of skin cancer from becoming resistant to treatment.
Investigators at the University of California, Irvine report that they have uncovered a specific mutation in the ATR gene that allows melanoma tumor cells to remain undetected by the immune system.
Dietary fat intake might promote the growth of melanoma tumors harboring BRAF V600E mutations, and lipid-lowering drugs can slow that growth, according to a mouse study.
There is a lot of interest in a new treatment that kills approximately 90% of melanoma cancer cells, an astounding accomplishment for Richard Neubig, MD, PhD, who serves as chairperson of pharmacology toxicology at Michigan State University.
Canadian researchers might have discovered why melanoma is more aggressive in men than women: decreased expression of a melanoma tumor suppressor gene on the sex chromosomes.
Scientists have found a way to detect earlier if Merkel cell carcinoma (MCC) is recurring in patients. They have published a paper in the journal Cancer demonstrating how an immune system marker may be able to outperform and supplement imaging studies for recurrence of MCC.